Gainers & Losers Of Mar.21: PULM, AST, GNMX, AXSM, LJPC...

(RTTNews) - The following are some of the biotech stocks that made their way onto the Day's Gainers & Losers' list of March 21, 2017.

GAINERS

1. Pulmatrix Inc. (PULM)

Gained 29.32% to close Tuesday's (Mar.21) trading at $3.60.

News: The Company has received European Patent for its inhaled drug delivery technology iSPERSE.

The EU patent follows on similar patents that Pulmatrix has been granted in the United States and Japan. PUR1900, PUR1500 and PUR0200 are Pulmatrix's product candidates based on the iSPERSE technology.

Near-term catalysts:

-- The Company expects pre-clinical data on PUR1900 targeting fungal infections for severe asthma and cystic fibrosis patients in the first half of 2017 -- Secure a strategic partner(s) on PUR0200, the company's most-advanced drug candidate, in the first half of 2017. PUR0200 is a novel dry powder formulation of a currently marketed once daily LAMA bronchodilator Spiriva HandiHaler, for the treatment of chronic obstructive pulmonary disease. PUR0200 is currently being developed in Europe based on PK bioequivalence, and the US development program is being planned. -- Pulmatrix intends to seek a pre-IND meeting with the FDA to inform the US clinical development path for PUR0200 in the second half of 2017. -- Continue CMC development work in the first half of 2017 to support a future European pivotal pharmacokinetic bioequivalence approval study as well as the US development path.

2. ESSA Pharma Inc. (EPIX)

Gained 15.30% to close Tuesday's trading at $3.24.

News: No news

Near-term catalyst:

The Company's lead clinical product candidate is EPI-506, under phase 1/2 clinical trial in men with metastatic castrate-resistant prostate cancer.

ESSA expects to report results from the phase I portion of the trial and initiate the phase II part at the established dose during the first half of calendar 2017.

3. Asterias Biotherapeutics Inc. (AST)

Gained 6.92% to close Tuesday's trading at $3.40.

News: The sixth and final patient in the Company's ongoing SCiStar study has further confirmed previously-announced motor function improvements at 6-months following administration of AST-OPC1.

The SCiStar study is a phase 1/2a dose escalation trial evaluating AST-OPC1, administered at up to 20 million AST-OPC1 cells, in as many as 35 patients with subacute cervical spinal cord injury. AST-OPC1 consists of neural cells known as oligodendrocyte progenitor cells, which are produced from human embryonic stem cells.

The sixth and final patient in the 10 million cell cohort has shown upper extremity motor function improvement at 3 months and further improvement at 6 months. This particular patient's hand and arm function had actually been deteriorating prior to receiving treatment with AST-OPC1, stated Edward Wirth III, Chief Medical Officer.

LOSERS

1. Aevi Genomic Medicine Inc. (GNMX)

Lost 20.81% to close Tuesday's trading at $1.83, falling for the second straight day.

News: No news

On March 20th, the Company announced that its phase 2/3 efficacy study of AEVI-001 in adolescent patients with ADHD (attention-deficit/hyperactivity disorder) who have genetic disorders impacting the mGluR network did not meet primary endpoint.

The study, dubbed SAGA, did not meet the primary endpoint of reduction on the ADHD rating scale (ADHD-RS) compared to placebo. The news sent the stock plunging 59.38% that day to $2.21.

2. Axsome Therapeutics Inc. (AXSM)

Lost 18.18% to close Tuesday's trading at $3.60.

News: The Company has priced its public offering of common stock at $3.74 per share.

Axsome has offered to sell 3.74 million shares of its common stock at a public offering price of $3.74 per share. The gross proceeds from the offering are expected to be approximately $14 million. The offering is expected to close on or about March 24, 2017.

The underwriter has a 30-day option to purchase up to 561,497 additional shares of common stock.

3. Atossa Genetics Inc. (ATOS)

Lost 11.03% to close Tuesday's trading at $1.29.

News: No news

Near-term catalyst:

The Company's lead product candidate is Fulvestrant. A phase II study of Fulvestrant administered with patented microcatheters in patients with ductal carcinoma in situ or breast cancer who are scheduled for lumpectomy or mastectomy, is underway. The study is expected to be fully enrolled by August of this year.

4. Calithera Biosciences Inc. (CALA)

Lost 13.77% to close Tuesday's trading at $10.65.

News: The Company announced that it intends to offer and sell 4.5 million shares of its common stock in an underwritten public offering.

5. La Jolla Pharmaceutical Company (LJPC)

Lost 11.39% to close Tuesday's trading at $34.06.

News: The Company intends to offer and sell $100 million shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement.

6. Dimension Therapeutics Inc. (DMTX)

Lost 12.50% to close Tuesday's trading at $1.75.

News: No news

Near-term catalyst:

Initial data from phase 1/2 clinical trial of DTX301 for the treatment of ornithine transcarbamylase (OTC) deficiency are expected in the second half of this year.